Keyword: Teva Pharmaceutical
Teva's Copaxone is losing ground to generic competition—and the company's newer drugs aren’t taking off fast enough to make up for the loss.
Mylan has set its list price for its Advair copy at a 70% discount to the brand. But the move may not be as dramatic as it seems.
Immunomedics says it will meet with the FDA to discuss the CRL it got for manufacturing, while Teva has a new union agreement in place.
Roche could use a speedy Kadcyla label expansion to help quiet concerns about mounting biosimilar competition to its aging blockbusters.
UnitedHealthcare's pharmacy benefits outfit OptumRx picked Amgen and Eli Lilly CGRP drugs for its preferred coverage list, handing Teva a setback.
Despite new competition from CGRP migraine prevention drugs, Allergan executives contend Botox can continue to grow.
CVS' coverage decision for Amgen's Aimovig marks a setback for the company's launch and a boost for rivals Teva and Eli Lilly.
What kind of difference can one year make? Just ask some Teva analysts, who are upbeat that the drugmaker's cost-cutting measures are paying off.
Thanks to groundwork laid by the feds, UnitedHealthcare is suing dozens of generics companies for alleged price fixing—and it wants its money back.
Teva has reaped plenty of tax benefits from its home country in recent years. But now the Israeli government reportedly wants some of that money back.